Revolution Medicines (NASDAQ:RVMD) Stock Gets Price Target Increase from Guggenheim

Revolution Medicines (NASDAQ:RVMD) had its price objective upped by stock analysts at Guggenheim from $275.00 to $298.00 in a research report issued on Thursday, Benzinga reports. The firm currently has a “buy” rating on the stock. Guggenheim‘s price objective would indicate a potential upside of 54.98% from the stock’s current price.

RVMD has been the topic of a number of other research reports. Royal Bank Of Canada boosted their target price on shares of Revolution Medicines from $259.00 to $260.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 14th. Brookline Capital Markets assumed coverage on shares of Revolution Medicines in a report on Monday, September 28th. They issued a “buy” rating and a $318.00 price target for the company. TD Cowen reissued a “buy” rating and issued a $250.00 price target on shares of Revolution Medicines in a report on Wednesday, October 21st. Evercore restated an “outperform” rating and issued a $320.00 price target on shares of Revolution Medicines in a research report on Thursday, August 27th. Finally, UBS Group boosted their price objective on shares of Revolution Medicines from $220.00 to $265.00 and gave the stock a “buy” rating in a report on Friday, August 28th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $263.15.

Revolution Medicines Stock Up 8.2%

Shares of Revolution Medicines stock traded up $14.63 during trading on Thursday, hitting $192.28. 4,496,326 shares of the stock traded hands, compared to its average volume of 1,940,895. The stock has a market cap of $41.21 billion, a P/E ratio of -21.11 and a beta of 1.44. The company has a debt-to-equity ratio of 0.40, a quick ratio of 11.38 and a current ratio of 11.38. Revolution Medicines has a twelve month low of $58.91 and a twelve month high of $224.31. The company has a fifty day moving average price of $196.88 and a two-hundred day moving average price of $157.56.

Revolution Medicines (NASDAQ:RVMD) last posted its earnings results on Wednesday, November 4th. The company reported ($1.90) EPS for the quarter, topping the consensus estimate of ($2.35) by $0.45. The business had revenue of $197.56 million for the quarter, compared to analyst estimates of $25.58 million. During the same period in the previous year, the company earned ($1.61) earnings per share. Equities research analysts predict that Revolution Medicines will post -8.94 EPS for the current fiscal year.

Insider Activity

In other news, CFO Jack Anders sold 4,053 shares of the firm’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $199.24, for a total value of $807,519.72. Following the completion of the sale, the chief financial officer directly owned 119,216 shares in the company, valued at approximately $23,752,595.84. This trade represents a 3.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Alan Sandler sold 6,309 shares of the firm’s stock in a transaction dated Tuesday, September 29th. The shares were sold at an average price of $202.14, for a total transaction of $1,275,301.26. Following the completion of the sale, the insider owned 52,559 shares of the company’s stock, valued at $10,624,276.26. The trade was a 10.72% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 290,991 shares of company stock worth $59,422,765. 7.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Aberdeen Group plc grew its holdings in Revolution Medicines by 303.1% during the third quarter. Aberdeen Group plc now owns 576,371 shares of the company’s stock valued at $118,306,000 after purchasing an additional 433,393 shares during the period. Allworth Financial LP raised its holdings in Revolution Medicines by 9.0% in the third quarter. Allworth Financial LP now owns 2,442 shares of the company’s stock worth $457,000 after purchasing an additional 202 shares during the period. R Squared Ltd acquired a new stake in Revolution Medicines in the third quarter worth $304,000. Fifth Third Bancorp raised its holdings in Revolution Medicines by 56.2% in the third quarter. Fifth Third Bancorp now owns 4,100 shares of the company’s stock worth $842,000 after purchasing an additional 1,475 shares during the period. Finally, Maryland State Retirement & Pension System raised its holdings in Revolution Medicines by 14.6% in the third quarter. Maryland State Retirement & Pension System now owns 11,608 shares of the company’s stock worth $2,383,000 after purchasing an additional 1,478 shares during the period. 94.34% of the stock is currently owned by institutional investors.

Key Headlines Impacting Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Strong early Rasonque sales: Revolution Medicines reported $197.6 million in third-quarter revenue, beating estimates, with Rasonque generating that amount in just five weeks after its U.S. launch. The company said more than 5,000 patients had been treated. The quarterly loss per share also came in narrower than analysts expected. Zacks article on Q3 results and Rasonque uptake
• Positive Sentiment: Analyst targets moved higher: HC Wainwright raised its target to $350 and maintained a Buy rating. RBC lifted its target to $321 with an Outperform rating; Guggenheim, Truist and TD Cowen also raised targets and retained positive ratings. These revisions signal optimism about the drug’s commercial potential and pipeline. HC Wainwright recommendations RBC target increase
• Neutral Sentiment: Long-term opportunity, but expectations are high: Rasonque’s clinical results and potential expansion into other solid tumors support the pipeline outlook. However, commentary noted that RVMD’s roughly $40 billion valuation already reflects substantial expectations, making sustained launch growth and upcoming clinical results important. Seeking Alpha analysis of Q3 results
• Negative Sentiment: Some long-range forecasts were cut: Brookline Capital Markets lowered its FY2029 EPS estimate to $8.49 from $8.94 and its FY2030 estimate to $17.41 from $18.15, though it kept a Buy rating and a $318 target.

Revolution Medicines Company Profile

Revolution Medicines, Inc is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company’s research centers on RAS proteins, which can contribute to the growth of many cancers.

The company’s pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.